ADRB1: IHC Expression in Cancer and Radioligand Target Profile
ADRB1, adrenoceptor beta 1, is a cell-surface protein (GPCR). In Human Protein Atlas immunohistochemistry, ADRB1 staining is highest in kidney cancer (56% of samples positive), glioma (40% of samples positive) and ovarian cancer (9% of samples positive). Evidence on whether ADRB1 internalizes is mixed. Clinical status: FDA-approved drug (any modality).
Is ADRB1 the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.
Analyze ADRB1 freeIs ADRB1 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ⚠️ Tumor expression: Medium IHC staining in kidney cancer, 56% of samples positive.
- ⚠️ Internalization: Mixed evidence.
- ✅ Clinical precedent: FDA-approved drug (any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
ADRB1 IHC staining by cancer type
Protein expression of ADRB1 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Kidney Cancer | 0.37 | Medium | 56% |
| Glioma | 0.23 | Medium | 40% |
| Ovarian Cancer | 0.06 | Low | 9% |
| Liver Cancer | 0.03 | Low | 9% |
Not detected by IHC in: skin cancer, colorectal cancer, head and neck cancer, lymphoma, breast cancer, melanoma, thyroid cancer, bladder cancer, neuroendocrine tumors, cervical cancer, lung cancer, pancreatic cancer, prostate cancer, gastric cancer, testicular cancer, endometrial cancer.
Is ADRB1 internalized?
Uncertain. Insufficient literature found.
ADRB1 clinical trials
FDA-approved drug (any modality). Nuclens hasn't indexed trials for ADRB1 yet. Search ClinicalTrials.gov for ADRB1 trials.
ADRB1 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See ADRB1 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
ADRB1 gene essentiality (DepMap)
CRISPR knockout effect across 1250 cancer cell lines: 0.10 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related kidney cancer radioligand targets
EGFR · c-MET (MET) · HER3 (ERBB3) · ITGAV · STEAP2 · Mesothelin (MSLN) · SSTR2 · HER2 (ERBB2)
See all radioligand therapy targets in kidney cancer.
See how ADRB1 ranks against 15,000 targets for your indication.
Analyze ADRB1 freeData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.